Insulet Co. (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have received a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $292.06.

PODD has been the topic of several research analyst reports. Wells Fargo & Company boosted their price objective on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group increased their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. boosted their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Citigroup raised their price target on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, Raymond James reiterated an “outperform” rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st.

Insider Transactions at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PODD. SBI Securities Co. Ltd. purchased a new stake in Insulet in the fourth quarter valued at $36,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Insulet during the fourth quarter worth about $42,000. SRS Capital Advisors Inc. lifted its holdings in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 56 shares during the last quarter. Friedenthal Financial acquired a new stake in shares of Insulet in the 4th quarter valued at about $57,000. Finally, TD Private Client Wealth LLC grew its stake in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 56 shares during the last quarter.

Insulet Stock Performance

NASDAQ:PODD opened at $258.75 on Friday. The company’s 50-day moving average is $271.69 and its two-hundred day moving average is $258.53. Insulet has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market capitalization of $18.17 billion, a price-to-earnings ratio of 44.69, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Analysts forecast that Insulet will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.